SEL24
Phase 1/2- Indications
- Acute myeloid leukemia
Company intelligence / Profile preview
Selvita provides comprehensive preclinical contract research services spanning from early drug discovery through to the clinical stage. The company has developed its own innovative drugs historically but now focuses on providing R&D services post-spinout of its proprietary oncology pipeline into Ryvu Therapeutics. It recently expanded into biologic drug discovery and development services with a focus on therapeutic antibodies[4][9]. No recent clinical results are publicly available for proprietary programs under the current corporate structure.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Selvita.